New drug combo tested to shrink stomach tumors before surgery
NCT ID NCT05507658
Summary
This study tested whether giving a combination of immunotherapy (tislelizumab) and chemotherapy (XELOX) before surgery could help people with advanced stomach or gastroesophageal junction cancer. It involved 28 patients to see if this approach safely shrank tumors and improved surgical outcomes. The goal was to provide a new treatment option to better control the disease before an operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710000, China
Conditions
Explore the condition pages connected to this study.